1. Home
  2. LWLG vs CBIO Comparison

LWLG vs CBIO Comparison

Compare LWLG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

N/A

Current Price

$3.01

Market Cap

625.9M

Sector

Industrials

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.95

Market Cap

507.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LWLG
CBIO
Founded
1991
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
625.9M
507.1M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
LWLG
CBIO
Price
$3.01
$12.95
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$7.00
★ $32.33
AVG Volume (30 Days)
★ 3.6M
195.3K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 15.79
N/A
EPS
★ N/A
N/A
Revenue
★ $236,855.00
$18,500.00
Revenue This Year
N/A
N/A
Revenue Next Year
$257.14
$37.50
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 147.74
N/A
52 Week Low
$2.83
$8.72
52 Week High
$18.71
$27.41

Technical Indicators

Market Signals
Indicator
LWLG
CBIO
Relative Strength Index (RSI) 33.95 43.44
Support Level N/A $11.78
Resistance Level $5.73 $13.54
Average True Range (ATR) 0.45 1.10
MACD -0.12 -0.03
Stochastic Oscillator 8.79 20.31

Price Performance

Historical Comparison
LWLG
CBIO

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: